Pancreatic NeoplasmsCHIRPANNCT02871336
Pancreatic Surgical Database
An observational study of Pancreatic Neoplasms, run by Institut Paoli-Calmettes at 1 site in France.
Trial summary
This data base has been set in order to gather medical and surgical information from patients who have undergone surgery for pancreatic cancer, at Institut Paoli Calmettes or Assistance Publique des Hôpitaux de Marseille, France. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Neoplasms
- What is being tested?
- Data collection
- How many people
- 1,500 participants
- Where
- 1 siteFrance
- Study dates
- Nov 2014to Nov 2030
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient with a pancreatic cancer who has undergone surgery
Who may be able to join
- Patient >18 ans
- Surgery for a pancreatic cancer
Who cannot join
- Patient refusal to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Institut Paoli Calmettes
Marseille, Bouches du Rhone, 13009
Dominique GENRE, MD, 33 4 91 22 37 78, drci.up@ipc.unicancer.fr
About this study
This data base has been set in order to gather medical and surgical information from patients who have undergone surgery for pancreatic cancer, at Institut Paoli Calmettes or Assistance Publique des Hôpitaux de Marseille, France.
- Conditions
- Pancreatic Neoplasms
- Being tested
- Data collection
- Keywords
- Cata collection, Pancreatic cancer surgery
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Data collectionOther
What is being measured
The primary outcome is the main question the study is designed to answer.
Optimization of the surgical care of the patients
Collection of clinical and surgical data for future research studies
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2016 (estimated)
- Study startNov 2014
- Primary completionNov 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Pancreatic NeoplasmsStudies of the same condition, open and under way.
- More trials run by Institut Paoli-CalmettesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,500 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Institut Paoli-Calmettes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Olivier Turrini, MD,PhD, Principal investigator, Institut Paoli-CalmettesVincent Moutardier, Principal investigator, Assistance Publique des Hôpitaux de MarseilleJean HARDWIGSEN, Principal investigator, Assistance Publique des Hôpitaux de MarseilleMehdi Ouassi, Principal investigator, Assistance Publique des Hôpitaux de Marseille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02871336
- Sponsor's protocol ID
- CHIRPAN
- Acronym
- CHIRPAN
- Status last verified
- Aug 2016
- First submitted
- 3 Aug 2016
- Last updated
- 18 Aug 2016
- Results posted
- No
- Data monitoring committee
- No
Publications
De Crignis L, Garnier J, Ewald J, Palen A, Piana G, Izaaryene J, Delpero JR, Turrini O. Preoperative liver arterial conditioning in patients scheduled for a Mayo Clinic class Ia distal pancreatectomy: embolization or ligation? HPB (Oxford). 2023 Apr;25(4):439-445. doi: 10.1016/j.hpb.2023.01.007. Epub 2023 Jan 20.
PubMed 36801197Palen A, Garnier J, Ewald J, Delpero JR, Turrini O. Readmission after pancreaticoduodenectomy: Birmingham score validation. HPB (Oxford). 2023 Feb;25(2):172-178. doi: 10.1016/j.hpb.2022.08.002. Epub 2022 Aug 20.
PubMed 36437219
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pancreatic Surgical Database
- ClinicalTrials.gov ID
- NCT02871336
- Acronym / sponsor ID
- CHIRPAN / CHIRPAN
- Conditions
- Pancreatic Neoplasms
- Keywords
- Cata collection, Pancreatic cancer surgery
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Institut Paoli-CalmettesUniversity, hospital or other
- Study start
- Nov 2014
- Primary completion
- Nov 2030 (estimated)
- First posted
- 18 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This data base has been set in order to gather medical and surgical information from patients who have undergone surgery for pancreatic cancer, at Institut Paoli Calmettes or Assistance Publique des Hôpitaux de Marseille, France.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient with a pancreatic cancer who has undergone surgery
Key inclusion criteria (2 listed)
- Patient >18 ans
- Surgery for a pancreatic cancer
Key exclusion criteria (1 listed)
- Patient refusal to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Data collection | Other | – |
Primary outcome
Optimization of the surgical care of the patients
Time frame: 5 years
Collection of clinical and surgical data for future research studies
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2016.
- Derived from this study: PubMed 36801197De Crignis L, Garnier J, Ewald J, Palen A, Piana G, Izaaryene J, Delpero JR, Turrini O. Preoperative liver arterial conditioning in patients scheduled for a Mayo Clinic class Ia distal pancreatectomy: embolization or ligation? HPB (Oxford). 2023 Apr;25(4):439-445. doi: 10.1016/j.hpb.2023.01.007. Epub 2023 Jan 20.
- Derived from this study: PubMed 36437219Palen A, Garnier J, Ewald J, Delpero JR, Turrini O. Readmission after pancreaticoduodenectomy: Birmingham score validation. HPB (Oxford). 2023 Feb;25(2):172-178. doi: 10.1016/j.hpb.2022.08.002. Epub 2022 Aug 20.
Related trials for Pancreatic Neoplasms
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer
RecruitingPhase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
RecruitingPhase 1/2
Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors
Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 1
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Active, not recruitingPhase 2
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
Pancreatic Cancer, Circulating Tumor Cell
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Olivier Turrini, MD,PhD principal investigator
Institut Paoli-Calmettes
Vincent Moutardier principal investigator
Assistance Publique des Hôpitaux de Marseille
Jean HARDWIGSEN principal investigator
Assistance Publique des Hôpitaux de Marseille
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Neoplasms, run by Institut Paoli-Calmettes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dominique Genre, MD (0033491223778, drci.up@ipc.unicancer.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Optimization of the surgical care of the patients (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02871336, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2016.